These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23946724)

  • 1. DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes.
    Aroor A; McKarns S; Nistala R; DeMarco V; Gardner M; Garcia-Touza M; Whaley-Connell A; Sowers JR
    Cardiorenal Med; 2013 Apr; 3(1):48-56. PubMed ID: 23946724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.
    Aroor AR; McKarns S; Demarco VG; Jia G; Sowers JR
    Metabolism; 2013 Nov; 62(11):1543-52. PubMed ID: 23932846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.
    Zhang J; Chen Q; Zhong J; Liu C; Zheng B; Gong Q
    Front Immunol; 2019; 10():1050. PubMed ID: 31134095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Range of adiposity and cardiorenal syndrome.
    Pazos F
    World J Diabetes; 2020 Aug; 11(8):322-350. PubMed ID: 32864046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Links between Central Obesity and Cardiorenal Metabolic Diseases.
    Al-Chalabi S; Syed AA; Kalra PA; Sinha S
    Cardiorenal Med; 2024; 14(1):12-22. PubMed ID: 38171343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
    McKillop AM; Stevenson CL; Moran BM; Abdel-Wahab YHA; Flatt PR
    Peptides; 2018 Feb; 100():165-172. PubMed ID: 29412816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
    Fadini GP; Avogaro A
    Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system.
    Lastra G; Sowers JR
    Horm Mol Biol Clin Investig; 2013 Sep; 15(2):49-57. PubMed ID: 25436732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?
    Bender SB; McGraw AP; Jaffe IZ; Sowers JR
    Diabetes; 2013 Feb; 62(2):313-9. PubMed ID: 23349535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
    Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
    Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.
    Aroor AR; Manrique-Acevedo C; DeMarco VG
    Cardiovasc Diabetol; 2018 Apr; 17(1):59. PubMed ID: 29669555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus.
    Yousefzadeh P; Wang X
    J Diabetes Res; 2013; 2013():459821. PubMed ID: 23710467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
    Sowers JR; Whaley-Connell A; Epstein M
    Ann Intern Med; 2009 Jun; 150(11):776-83. PubMed ID: 19487712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.
    Chalmers L; Kaskel FJ; Bamgbola O
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):352-64. PubMed ID: 17045221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure-lowering effects of incretin-based diabetes therapies.
    Lovshin JA; Zinman B
    Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.